Inclisiran, the billion-dollar drug, to lower LDL cholesterol - is it worth it?

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• RNA Therapeutics

Background:

• Hypercholesterolemia management often requires non-statin therapies when statins are insufficient.
• Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, including monoclonal antibodies, reduce LDL cholesterol and cardiovascular events.
• Inclisiran represents a new class of PCSK9-targeting therapy as a small interfering RNA (siRNA) molecule.

Purpose of the Study:

• To evaluate the efficacy and safety of inclisiran in treating hypercholesterolemia.
• To assess inclisiran's role in managing heterozygous familial hypercholesterolemia.
• To review Phase 3 clinical trial data for inclisiran.

Main Methods:

• Focus on Phase 3 clinical trials assessing inclisiran.
• Evaluation of inclisiran's impact on LDL cholesterol levels.
• Assessment of adverse effects associated with inclisiran treatment.

Main Results:

• Inclisiran demonstrates significant reductions in LDL cholesterol.
• The therapy exhibits a favorable safety profile with minimal adverse effects.
• Promising initial findings suggest potential for widespread use.

Conclusions:

• Inclisiran shows considerable promise in lowering LDL cholesterol effectively and safely.
• Cardiovascular outcomes trials are pending, limiting direct comparison with PCSK9 monoclonal antibodies.
• The cost and long-term accessibility of inclisiran require further investigation, mirroring challenges with existing PCSK9 inhibitors.